Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorZhujiang Hospital
About this trial
To provide a comprehensive MALDI-TOF mass spectrometry method for detecting, characterizing, and quantifying M-protein, and to track M-protein in a very sensitive and specific manner during patient treatment, providing a more precise test for diagnosing disease and monitoring patient response to treatment.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
All the patients with Multiple myeloma hospitalized in Zhujiang hospital will be eligible to be enrolled. Also, their age- and sex- matched healthy controls making a physical examination in Zhujiang hospital will be eligible to be enrolled
Trial design
Design model
Case-control
Time perspective
Other
Treatments tested in this trial
Observational studies, no intervention
Other interventionObservational studies, no intervention
Treatment groups
200 Participants
are divided into 2 treatment groupsGroup A: Multiple myeloma1 intervention
Group B: Healthy control1 intervention
Trial outcomes
Primary outcomes
1
M-protein
M-protein in urine and serum detected using MALDI-TOF Mass Spectrometry
Time frame
baselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Zhujiang Hospital
Lead sponsor
National Natural Science Foundation of China
Collaborator
Source ClinicalTrials.gov